Amylyx Pharmaceuticals, Inc. (AMLX) Stock Analysis
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Engine safety override at $12.92: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10 and A.R:R 4.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Below-average business quality; Negative price momentum.
Amylyx Pharmaceuticals is a clinical-stage pharmaceutical company developing avexitide (Phase 3 LUCIDITY trial complete for post-bariatric hypoglycemia, topline data expected Q3 2026) and AMX0035 (Phase 2 for Wolfram syndrome). The company withdrew its previous commercial... Read more
Sell if holding. Engine safety override at $12.92: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10 and A.R:R 4.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.7/10, moderate confidence.
Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 79d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — Amylyx Pharmaceuticals, Inc.
Latest news
- Amylyx Pharmaceuticals Publishes Data From Weeks 24, 48 Of Its Phase 2 HELIOS Study Of AMX0035 To Treat Wolfram Syndrome — benzinga May 15, 2026 positive
- 12 Health Care Stocks Moving In Friday's Pre-Market Session — benzinga May 8, 2026 neutral
- Amylyx Pharma Q1 EPS $(0.37), Inline, Cash, Cash Equivalents, And Short-Term Investments Were $279.8M, With Expected Cas — benzinga May 7, 2026 neutral
- Amylyx Launches Early Access Program For Experimental Hypoglycemia Drug, Expands Access To Avexitide Ahead Of Phase 3 Re — benzinga May 5, 2026 positive
- Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $21 — benzinga Apr 28, 2026 positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Concentration Risks(10-K Item 1A)
- HIGHpipelineavexitide10-K Item 1A: 'We currently depend heavily on the success of avexitide, our most advanced product candidate, and AMX0035.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers·2 ceiling hits
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Volatile — 6.1% daily ATR makes tight stops impractical. Position-size conservatively.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $12.92: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10 and A.R:R 4.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $12.48. Score 4.7/10, moderate confidence.
Take-profit target: $20.36 (+57.2% upside). Prior stop was $12.48. Stop-loss: $12.48.
Concentration risk — Pipeline: avexitide; Quality below floor (1.2 < 4.0).
Amylyx Pharmaceuticals, Inc. trades at a P/E of N/A (forward -10.5). TrendMatrix value score: 9.0/10. Verdict: Sell.
18 analysts cover AMLX with a consensus score of 4.3/5. Average price target: $23.
What does Amylyx Pharmaceuticals, Inc. do?Amylyx Pharmaceuticals is a clinical-stage pharmaceutical company developing avexitide (Phase 3 LUCIDITY trial complete...
Amylyx Pharmaceuticals is a clinical-stage pharmaceutical company developing avexitide (Phase 3 LUCIDITY trial complete for post-bariatric hypoglycemia, topline data expected Q3 2026) and AMX0035 (Phase 2 for Wolfram syndrome). The company withdrew its previous commercial product RELYVRIO for ALS in 2024 and currently has no approved products or revenue.